ABVC BioPharma, Inc
ABVC BioPharma, Inc. is a Nevada-incorporated, clinical-stage biopharmaceutical company developing plant-derived investigational drugs and a medical device, with programs focused on central nervous system (CNS) disorders and oncology/hematology. Its pipeline comprises seven drug candidates and one device, largely licensed from related parties, and the company’s operating model centers on advancing assets through clinical development and monetizing them via out-licensing and collaborations. To date, ABVC has generated only unsubstantial revenue, primarily from outlicensing intellectual property and providing CDMO services rather than from product sales. The company runs development and partner-facing activities across the U.S. and Asia-Pacific, including clinical collaborations with institutions such as Stanford University Medical Center and Taipei Veterans General Hospital.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePlant-derived investigational drugs targeting CNS indications such as MDD and ADHD (e.g., ABV-1504, ABV-1505).
Plant-derived investigational drugs for cancers and hematologic disorders (e.g., ABV-1501, ABV-1519, ABV-1702, ABV-1703, ABV-1601).
ABV-1701 Vitargus device program for retinal detachment/vitreous hemorrhage treatment pathways.
Licensing of ABVC intellectual property and regional partnering arrangements (e.g., BioHopeKing for selected Asian markets).
Contract development/manufacturing-related services provided to external parties as a source of non-product revenue.
Customers
ABVC’s near-term customers are primarily commercial partners rather than end patients, reflecting a business model built around out-licensing and co-development of pipeline assets. Potential counterparties include biotechnology and pharmaceutical companies seeking rights to develop and commercialize ABVC’s CNS and oncology/hematology candidates, as well as the Vitargus device, in specific territories. The company also interacts with research institutions and principal investigators that conduct Phase II trials, which are critical enablers of clinical progress but are not necessarily revenue-generating customers. In addition, ABVC provides CDMO services, implying a customer base of companies that outsource development/manufacturing work. The ability to secure partners—particularly in the U.S.—is a key determinant of whether ABVC can translate clinical assets into recurring licensing milestones/royalties or service revenue.
License or co-develop CNS and oncology/hematology candidates; value is driven by U.S. commercial potential and regulatory pathway execution.
Acquire territorial rights and collaborate on development/commercialization in selected Asian markets (e.g., Taiwan/Asia partners).
Purchase contract development/manufacturing-related services to supplement ABVC’s limited pipeline monetization revenue.
Conduct Phase II trials and generate clinical data needed to attract licensing partners and progress regulatory submissions.
Geography
ABVC operates with business operations in Taiwan and collaborative activities in the United States and Japan, reflecting its Asia-Pacific sourcing of technologies and U.S.-centric clinical and partnering ambitions. The company reports that sales to customers outside the United States accounted for 100% of sales in both 2025 and 2024, indicating that monetization to date has been entirely international. ABVC’s cost base and cash flows are exposed to currency movements because substantial revenues and expenses are denominated in New Taiwan Dollars and U.S. dollars. The international footprint also increases exposure to cross-border compliance requirements (including anti-corruption and export controls) and to China–Taiwan geopolitical instability, which can affect staffing, partner engagement, and operational continuity.
Risks
ABVC faces core clinical-stage biotech risks: long development timelines, high R&D spend, and binary outcomes from clinical trials that determine whether assets can be licensed or approved. The company’s business model heightens partnering risk—if it cannot secure or maintain strategic collaborations for candidates that are not fully licensed out, it may need to fund development internally and raise additional capital. International operations add material exposure to regulatory and compliance complexity (including FCPA and local anti-corruption laws), currency fluctuations between the U.S. dollar and New Taiwan Dollar, and China–Taiwan geopolitical instability. Execution risk also includes dependence on CROs and trial sites for data generation and FDA communications, as well as potential disruptions from public health events (e.g., COVID-19) that can slow enrollment and disrupt supply chains. Finally, as a small issuer, it is exposed to financing and listing risks (e.g., Nasdaq compliance) that can constrain capital access.
- Licensors may terminate license agreementsImpact: CriticalLikelihood: High
Pipeline assets are licensed (including from related parties); termination could halt R&D and eliminate future partnering value.
- Inability to identify and align with commercial partners (especially in the U.S.)Impact: HighLikelihood: High
ABVC relies on out-licensing/co-development to monetize assets; delays reduce competitiveness and extend cash burn.
Exposure - International operations and China–Taiwan geopolitical instabilityImpact: HighLikelihood: Medium
Operations and key employees are in Taiwan and partners are in Asia; instability can disrupt operations, compliance, and fund transfers.
Exposure: Taiwan operations; cross-border collaborations
- CRO/vendor dependency for clinical development and regulatory interactionsImpact: MediumLikelihood: High
Inability to secure capable CROs can delay data generation and FDA communications, reducing partnerability of assets.
- COVID-19 and other public health disruptionsImpact: MediumLikelihood: Medium
Can impair patient recruitment, disrupt supply chains for ABV-1504/1505/1601, and divert management resources.
Exposure: Clinical trial timelines and supply chain
Accounting
Judgemental itemsTiming depends on contract terms, milestones, and variable consideration; small changes can swing reported revenue.
Impact: Affects revenue timing, deferred revenue/contract assets, and period comparability
Determining performance obligations and whether revenue is recognized over time affects quarterly volatility.
Impact: Affects service revenue timing and gross margin presentation
Reclassifying related-party balances between operating and financing changes interpretation of operating cash burn.
Impact: Affects operating vs financing cash flow comparability across periods
Clinical-stage reporting relies on judgments and non-cash charges that can obscure underlying cash consumption.
Impact: Affects net loss, operating expense trends, and valuation inputs
Similar listed companies
Publicly listed companies with a comparable business focus.
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
CNBX Pharmaceuticals Inc.
CNBX · Pharmaceutical Preparations
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
Whitehawk Therapeutics, Inc.
WHWK · Pharmaceutical Preparations
Last updated: 24/09/2026